top of page
Browse by category
Search


EASO recommends semaglutide and tirzepatide as first-line treatment for obesity
Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to...


Journal Watch 10/7/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


New framework for diagnosing obesity based on body fat distribution not BMI
A new framework for the diagnosis, staging and management of obesity in adults, launched by the European Association for the Study of...


EASO and ECPO issue joint warning regarding counterfeit obesity medications
The European Association for the Study of Obesity (EASO) and the European Coalition for People Living with Obesity (ECPO) have issued a...


IFSO-EC, EASO and ECPO issue joint statement on surgical tourism
The International Federation for the Surgery of Obesity and Metabolic Disorders, European Chapter (IFSO-EC), the European Association for...
Browse by tag






bottom of page

